McCune-Albright syndrome and disorders due to activating mutations of GNAS1

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 8, 2007, Pages 853-880

  Diaz, Alejandro ^a   Danon, Marco ^b   Crawford, John ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acromegaly; Aromatase inhibitors; Bisphosphonates; Caf au lait spots; Cushing's syndrome; G protein; Gigantism; Hyperprolactinemia; McCune Albright syndrome; Polyostotic fibrous dysplasia; Precocious puberty

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BROMOCRIPTINE MESILATE; CABERGOLINE; CALCITONIN; CARBIMAZOLE; CARBON DIOXIDE; CLODRONIC ACID; CYPROTERONE ACETATE; DOPAMINE RECEPTOR STIMULATING AGENT; FADROZOLE; FULVESTRANT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA 1 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; IODINE 131; KETOCONAZOLE; LETROZOLE; MEDROXYPROGESTERONE; METYRAPONE; OCTREOTIDE; PEGVISOMANT; PROPYLTHIOURACIL; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE; THIAMAZOLE; TRILOSTANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL CRAMP; ACROMEGALY; ADRENAL GLAND; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ALBRIGHT SYNDROME; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BEHAVIOR CHANGE; BONE DYSPLASIA; BONE PAIN; CAFE AU LAIT SPOT; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CUSHING SYNDROME; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EPISCLERITIS; EPISTAXIS; ERYTHEMA; GENE MUTATION; GLOSSITIS; HALLUCINATION; HEART DISEASE; HEPATITIS; HOT FLUSH; HUMAN; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; IRIDOCYCLITIS; KIDNEY CALCIFICATION; LAPAROSCOPIC SURGERY; LIVER DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; OSTEOMALACIA; OVARY CYST; PAIN; PARESTHESIA; PATHOGENESIS; PRECOCIOUS PUBERTY; PROGNOSIS; PROTEIN LOCALIZATION; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RICKETS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; THYROID ADENOMA; THYROIDECTOMY; VISUAL DISORDER; VOMITING;

EID: 34648813620     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.8.853     Document Type: Review

References (180)

1. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs. J Pediatr 1993; 123: 509-518.
2. Yoshimoto M, Nakayama M, Baba T, Uehara Y, Niikawa N, Ito M, Tsuji Y. A case of neonatal McCune-Albright syndrome with Cushing syndrome and hyperthyroidism. Acta Paediatr Scand 1991; 80: 984-987.
3. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction with precocious puberty in females. N Engl J Med 1937; 216: 727-746.
4. Freedman HJ. Disturbances of function of the suprarenal glands in children. Am J Dis Child 1932; 44: 1285-1292.
5. McCune DJ, Bruch H. Osteodystrophia fibrosa: report of a case in which the condition was combined with precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, with a review of the literature. Am J Dis Child 1937; 54: 806-848.
6. Weil H. Pubertas praecox und Knochenbruchigkeit. Klin Wochenschr 1922; 1:2114-2115.
7. Albright F, Reifenstein EC Jr. The Parathyroid Glands and Metabolic Bone Disease. Baltimore, MD: Williams and Wilkins, 1948; 264-266.
8. Von Recklinghausen FD. Die fibrose oder deformirende Ostitis, die Osteomalacie und die osteoplastistische Carcinose in ihren Gegenseitigen Beziehungen. Festschrift fur Rudolf Wirchow. Berlin: Reimer, 1891; 1.
9. Lichtenstein L. Polyostotic fibrous dysplasia. Arch Surg 1938; 36: 874-898.
10. Lichtenstein L, Jaffe HL. Fibrous dysplasia of bone: a condition affecting one, several, or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extra-skeletal abnormalities. Arch Pathol 1942; 33: 777-816.
11. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-95.
12. Laven JSE, Lumbroso S, Sultan C, Fauser BCJM. Dynamics of ovarian function in an adult woman with McCune-Albright syndrome. J Clin Endocrinol Metab 2001;86: 2625-2630.
13. Benedict PH. Endocrine features of Albright's syndrome. Metabolism 1962; 11: 30-45.
14. Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright and Albright hereditary osteodystrophy. Medicine 1996; 75:171-184.
15. De Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M, Cisternino M, de Sanctis V, Lucci M, Franzese A, Ghizzoni L, Pasquino AM, Segni M, Rigon F, Saggese G, Bertelloni S, Buzi F. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Pediatr Endocrinol Metab 1999; 12:817-826.
16. Lumbroso S, Paris F, Sultan C. Activating Gsα mutations: analysis of 113 patients with signs of McCune-Albright syndrome-a European Collaboration study. J Clin Endocrinol Metab 2004; 89:2107-2113.
17. Bareille P, Azcona A, Stanhope R. Multiple neonatal endocrinopathies in McCune-Albright syndrome. J Paediatr Child Health 1999; 35: 315-318.
18. Danon M, Crawford JD. The McCune-Albright syndrome. Ergeb Inn Med Kinderheilkd 1987; 55:81-115.
19. Hackett LJ, Chistopherson WM. Polyostotic fibrous dysplasia. J Pediatr 1949; 35: 767-771.
20. Arlien-Soberg U, Iversen T. Albright's syndrome. A brief survey and report of a case in a seven-year-old girl. Acta Paediatr 1956; 45: 558-568.
21. Comite F, Shawker TH, Pescovitz OH, Loriaux DL, Cutler GB. Cyclical ovarian function resistant to treatment with an analog of luteinizing hormone releasing hormone in McCune-Albright syndrome. N Engl J Med 1984; 311: 1032-1036.
22. Rieth KG, Comite F, Shawker TH, Cutler GB. Pituitary and ovarian abnormalities demonstrated by CT and ultrasound in children with features of the McCune-Albright syndrome. Radiology 1984; 153: 389-393.
23. Danon M, Robboy SJ, Kim S, Scully R, Crawford JD. Cushing syndrome, sexual precocity, and polyostotic fibrous dysplasia (Albright syndrome) in infancy. J Pediatr 1975; 87: 917-921.
24. D'Armiento M, Reda G, Camagne A, Tardella L. McCone-Albright syndrome: evidence for autonomous multiendocrine hyperfunction. J Pediatr 1983; 102: 584-586.
25. Foster CM, Ross JL, Shawker T, Pescovitz OH, Loriaux DL, Cutler GB, Comite F. Absence of pubertal gonadotropin secretion in girls with McCone-Albright syndrome. J Clin Endocrinol Metab 1984; 58: 1161-1165.
26. Wierman ME, Beardsworth DE, Mansfield MJ, Badger TM, Crawford JD, Crigler JF Jr, Bode HH, Loughlin JS, Kushner DC, Scully RE, et al. Puberty without gonadotropins. A unique mechanism of sexual development. N Engl J Med 1985; 312: 65-72.
27. Foster CM, Feuillan P, Padmanabhan V, Pescovitz OH, Beitins IZ, Comite F, Shawker TH, Loriaux DL, Cutler GB. Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 1986; 20: 859-863.
28. Holland FJ. Gonadotropin-independent precocious puberty. Endocrinol Metab Clin North Am 1991; 20: 191-200.
29. Lee PA, Van Dop C, Migeon CJ. McCune-Albright syndrome. Long term follow-up. JAMA 1986; 256: 2980-2984.
30. Malchoff CD, Reardon G, MacGillivray DC, Yamase H, Rogol AD, Malchoff DM. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 1994; 78: 803-806.
31. Feuillan PP, Jones J, Oerter KE, Manasco PK, Cutler GB. Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome. J Clin Endocrinol Metab 1991; 73: 1370-1373.
32. Pienkowski C, Lumbroso S, Bieth E, Sultan C, Rochiccioli P, Tauber M. Recurrent ovarian cyst and mutation of the Gs alpha gene in ovarian cyst fluid cells: what is the link with McCune-Albright syndrome? Acta Paediatr 1997; 86: 1019-1021.
33. Frisch L, Copeland K, Boepple P. Recurrent ovarian cyst in childhood: diagnosis of McCune-Albright syndrome by bone scan. Pediatrics 1992; 90: 102-104.
34. Román R, Johnson MC, Codner E, Boric MA, áVila A, Cassorla F. Activating GNAS1 gene mutations in patients with premature thelarche. J Pediatr 2004; 145: 218-222.
35. Scanlon EF, Burkett FE, Sener SF, Green OC, Traisman HS, Marr TJ, Victor TA, Crist ML. Breast carcinoma in an 11-year-old girl with Albright's syndrome. Breast 1980; 6: 6-9.
36. Tanabe Y, Nakahara S, Mitsuyama S, Minom O, Satoshi T. Breast cancer in a patient with McCune-Albright syndrome. Breast Cancer 1998; 5: 175-178.
37. Huston TL, Simmons RM. Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Breast J 2004; 10: 440-442.
38. Ahmad KN, Lennox B, Mack WS. Estimation of the volume of Leydig cells in man. Lancet 1969; ii: 461-464.
39. Lightner ES, Penny R, Frasier SD. Growth hormone excess and sexual precocity in polyostotic fibrous dysplasia (McCune-Albright syndrome). J Pediatr 1975; 98: 922-927.
40. Lightner ES, Winter JSD. Treatment of juvenile acromegaly with bromocriptine. J Pediatr 1981; 98: 494-496.
41. Giovannelli G, Bernasconi S, Banchini G. McCune-Albright syndrome in a male child: a clinical and endocrinologic enigma. J Pediatr 1978; 92: 220-226.
42. Coutant R, Lumbroso S, Rey R, Lahlou N, Venara M, Rouleau S, Sultan C, Limal JM. Macroorchidism due to autonomous hyperfunction of Sertoli cells and Gsα gene mutation: an unusual expression of McCune-Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab 2001; 86: 1778-1781.
43. Wasniewska M, De Luca F, Bertelloni S, Matarazzo P, Weber G, Crisafulli G, Valenzise M, Lala R. Testicular microlithiasis: an unreported feature of McCune-Albright syndrome in males. J Pediatr 2004; 145: 670-672.
44. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002; 87:5104-5112.
45. Mastorakos G, Mitsiades NS, Doufas AG, Koutras D. Hyperthryroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997; 7: 433-439.
46. Lawless ST, Reeves G, Bowen JR. The development of thyroid storm in a child with McCune-Albright syndrome after orthopedic-surgery. Am J Dis Child 1992; 146:1099-1102.
47. Gessl A, Freissmuth M, Czech T, Matula C, Hainfellner JA, Buchfelder M, Vierhapper H. Growth hormone-prolactin-thymtropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functional normal Gsα protein. J Clin Endocrinol Metab 1994; 79: 1128-1134.
48. Hamilton CR, Maloof F. Unusual types, of hyperthyroidism. Medicine 1973; 52: 195-215.
49. Andrews BS, Posen S, Podolsky S. Thyrotropin in Albright's syndrome with hyperthyroidism. Ann Intern Medicine 1974; 81: 561.
50. Tanaka T, Suwa S. A case of McCune-Albright syndrome with hyperthyroidism and vitamin D-resistant rickets. Helv Paediatr Acta 1977; 32: 263-273.
51. Brogan P, Khadilkar VV, Stanhope R. Occult T3 toxicosis in McCune-Albright syndrome. Horm Res 1997; 50: 105-106.
52. Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC. Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormonal studies. J Clin Endocrinol Metab 1990; 71: 1596-1601.
53. Lair-Milan F, Le Blevec G, Carel JC, Chaussain JL, Adamsbaum C. Thyroid sonographic abnormalities in McCune-Albright syndrome. Pediatr Radiol 1996; 26: 424-426.
54. Collins MT, Sarlis NJ, Merino MJ. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gsα mutations. J Clin Endocrinol Metab 2003; 88: 4413-4417.
55. Albers N, Jorgens S, Deiss D, Hauffa BP. McCune-Albright syndrome - the German experience. J Pediatr Endocrinol Metab 2002; 15 (Suppl 3): 897-901.
56. Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999; 134: 789-792.
57. MacMahon HE. Albright's syndrome-thirty years later (polyostotic fibrous dysplasia). Pathol Annu 1971; 6: 81-146.
58. Williamson EA, Johnson SJ, Foster S, Kendall-Taylor P, Harris PE. G protein gene mutations in patients with multiple endocrinopathies. J Clin Endocrinol Metab 1995; 80: 1702-1705.
59. Scurry MT, Bicknell JM, Fajans SS. Polyostotic fibrous dysplasia and acromegaly. Arch Intern Med 1964; 114: 40-45.
60. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989; 68:1148-1154.
61. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 1992; 15: 185-190.
62. Premawardhana LD, Vora JP, Mills R, Scanlon MF. Acromegaly and its treatment in the McCune-Albright syndrome. Clin Endocrinol (Oxf) 1992; 36: 605-608.
63. Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, Kiess W, Repp R, Rascher W, Doetsch J. Low prevalence of Gsα mutations in somatotroph adenomas of children and adolescents. Cancer Genet Cytogenet 2006; 166: 146-151.
64. Dötsch J, Kiess W, Hänze J, Repp R, Lüdecke D, Blum WF, Rascher W. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996; 81: 3839-3842.
65. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Prognostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83: 1604-1610.
66. Chanson P, Dib A, Visor A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994; 131: 229-234.
67. Obuobie K, Mullik V, Jones C, John R, Rees AE, Davies JS, Scanlon MF, Lazarus JH. McCune-Albright syndrome: growth hormone dynamics in pregnancy. J Clin Endocrinol Metab 2001; 86: 2456-2458.
68. Carr D, Mathie IK, Manners AR, Colman C. Hyperprolactinaemia in a patient with the McCune-Albright syndrome. Br J Obstet Gynaecol 1979; 86:330-331.
69. Ehrig U, Wilson DR. Fibrous dysplasia of bone and. primary hyperparathyroidism. Ann Intern Med 1972; 77: 234-238.
70. Cavanah SF, Dons RF. McCune-Albright syndrome: how many endocrinopathies can one patient have? South Med J 1993; 86: 364-367.
71. Hammami MM, al-Zahrani A, Butt A, Vencer LJ, Hussain SS. Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: absence of McCune-Albright syndrome mutations. J Endocrinol Invest 1997; 20: 552-558.
72. LaBagnara J Jr; Yuppa F, Klein MH. Fibrous dysplasia of the middle turbinate with primary hyperparathyroidism. Ear Nose Throat J 1998; 77: 552-553.
73. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 1996; 98: 30-35.
74. Auwerx J, Bouillon R. Mineral and bone metabolism in thyroid disease: a review. Q J Med 1986; 60: 737-752.
75. Kim SJ, Seok JW, Kim IJ, Kim YK, Jung DS, Kim DS. Fibrous dysplasia associated with primary hyperparathyroidism in the absence of the McCone-Albright syndrome: Tc-99m MIBI and Tc-99m MDP findings. Clin Nucl Med 2003; 28: 416-418.
76. Hahn SB, Lee SB, Kim DH. Albright's syndrome with hypophosphatemic rickets and hyperthyroidism-a case report. Yonsei Med J 1991; 32: 179-183.
77. Dutta S, Bagga A. McCune-Albright syndrome and hypophosphatemic rickets. Indian J Pediatr 1999; 66: 628-631.
78. Zung A, Chalew SA, Schwindinger WF, Levine MA, Phillip M, Jara A, Counts DR, Kowarski AA. Urinary cyclic adenosine 3′,5′-monophosphate response in McCune-Albright syndrome: clinical evidence for altered renal adenylate cyclase activity. J Clin Endocrinol Metab 1995; 80: 3576-3581.
79. Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P. Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res 2003; 18: 1235-1246.
80. Cole JA, Eber SL, Poelling RE, Thorne PK, Forte LR. A dual mechanism for regulation of kidney phosphate transport by parathyroid hormone. Am J Physiol 1987; 253: E221-E227.
81. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086.
82. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Kushiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigue J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663.
83. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112: 683-692.
84. Yamamoto T, Imanishi Y, Kinoshita E, Nakagomi Y, Shimizu N, Miyauchi A, Satomura K, Koshiyama H, Inaba M, Nishizawa Y, Jüppner H, Ozono K. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 2005; 23: 231-237.
85. Grant DB, Martinez L. The McCune-Albright syndrome without typical skin pigmentation. Acts Paediatr Scand 1983; 72: 467-478.
86. Tekin M, Bodurtha JN, Riccardi VM. Café au lait spots: the pediatrician's perspective. Pediatr Rev 2001; 22: 82-90.
87. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 1986; 29: 321-324.
88. Albright F. Polyostotic fibrous dysplasia: a defense of the entity. J Clin Endocrinol Metab 1947; 7: 307-324.
89. Benedict PH, Szabo G, Fitzpatrick TB, Sinesi SJ. Melanotic macules in Albright's syndrome and in neurofibromatosis. JAMA 1968; 205: 72-80.
90. Kim IS, Kim ER, Nam HJ, Chin MO, Moon YH, Oh MR, Yeo UC, Song SM, Kim JS, Uhm MR, Beck NS, Jin DK. Activating mutation of Gs alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Horm Res 1999; 52: 235-240.
91. Shenker A, Weinstein LS, Sweet DE, Spiegel AM. An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome. J Clin Endocrinol Metab 1994; 79: 750-755.
92. Harris WH, Dudley HR, Barry RJ. The natural history of fibrous dysplasia. J Bone Joint Surg 1962; 44A: 207-233.
93. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004; 19: 571-577.
94. Gurler T, Alper M, Gencosmanoglu R, Totan S, Guner U, Akin Y. McCune-Albright syndrome progressing with severe fibrous dysplasia. J Craniofac Surg 1998; 9: 79-82.
95. Lee JS, FitzGibbon E, Butman JA. Normal vision despite narrowing of the optic canal in fibrous dysplasia. N Engl J Med 2002; 347: 1670-1676.
96. Bocca G, de Vries J, Cruysberg JR, Optic neuropathy in McCune-Albright syndrome: an indication for aggressive treatment. Acts Paediatr 1998; 87: 599-600.
97. Pfeffer S, Molina E, Feuillan P, Simon TR. McCune-Albright syndrome: the patterns of scintigraphic abnormalities. J Nucl Med 1990; 31: 1474-1478.
98. Gebhardt MC, Mankin HJ. Advances in the management of bone tumors. In: Monaco AP, Simmons R, Ebert T, Jones RS, eds. Texbook of Surgery. New York: MacMillan, 1985; 73-84.
99. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77: 647-651.
100. Cohen MM Jr, Howell RE. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg 1999; 28: 366-371.
101. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Robey PG. Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 2000; 15: 120-128.
102. Hannon TS, Noonan K, Steinmetz R, Eugster EA, Levine MA, Pescovitz OH. Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone? J Pediatr 2003; 142: 532-538.
103. Marie PJ, de Pollak C, Chanson P, Lomri A. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997; 150: 1059-1069.
104. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P. Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997; 151: 1587-1600.
105. Inamo Y, Hanawa Y, Kin H, Okuni M. Findings on magnetic resonance imaging of the spine and femur in a case of McCune-Albright syndrome. Pediatr Radiol 1993; 23: 15-18.
106. Fraser WD, Walsh CA, Birch MA, Durham B, Dillon JP, McCreavy D, Gallagher JA. Parathyroid hormonerelated protein in the aetiology of fibrous dysplasia of bone in the McCune Albright syndrome. Clin Endocrinol (Oxf) 2000; 53: 621-628.
107. Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Robey. PG, Bianco P. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol 1999; 187: 249-258.
108. Schwartz DT, Alpert M. The malignant transformation of fibrous dysplasia. Am J Med Sci 1964; 247: 1-20.
109. Yabut SM Jr, Kenan S, Sissons HA, Lewis MM. Malignant transformation of fibrous dysplasia. A case report and review of the literature. Clin Orthop 1988; 228: 281-289.
110. Mazabraud A, Semat P, Roze R. A propos de l'association de fibromyxomes des tissus mous a la dysplasie fibreuse des os. Presse Med 1967; 75: 2223-2228.
111. Cabral CE, Guedes P, Fonseca T, Rezende JF, Cruz Júnior LC, Smith J. Polyostotic fibrous dysplasia associated with intramuscular myxomas: Mazabraud's syndrome. Skeletal Radiol 1998; 27: 278-282.
112. Faivre L, Nivelon-Chevallier A, Kottler ML, Robinet C, Khau Van Kien P, Lorcerie B, Munnich A, Maroteaux P, Cormier-Daire V, LeMerrer M. Mazabraud syndrome in two patients: clinical overlap with McCune-Albright syndrome. Am J Med Genet 2001; 99: 132-136.
113. Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome. Skeletal Radiol 1999; 28: 522-526.
114. Zumkeller W, Jassoy A, Lebek S, Nagel M. Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary, adenoma. J Pediatr Endocrinol Metab 2001; 14: 553-559.
115. Kairemo KJ, Verho S, Dunkel L. Imaging of McCune-Albright syndrome using bone single photon emission computed tomography. Eur J Pediatr 1999; 158: 123-126.
116. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000; 137: 403-409.
117. Alon US. Nephrocalcinosis. Curr Opin Pediatr 1997; 9: 160-165.
118. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
119. Klein I, Ojamaa K. Clinical review 36: Cardiovascular manifestations of endocrine disease. J Clin Endocrinol Metab 1992; 75: 339-342.
120. Farfel Z, Bourne HR, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med 1999; 340: 1012-1020.
121. Spiegel AM. Inborn errors of signal transduction: mutations in G proteins and G protein-coupled receptors as a cause of disease. J Inherit Metab Dis 1997; 20:113-121.
122. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992; 89: 5152-5156.
123. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 1995; 16: 259-270.
124. Candeliere GA, Roughley PJ, Glorieux FH. Polymerase chain reaction-based technique for the selective enrichment and analysis of mosaic arg201 mutations in G alpha s from patients with fibrous dysplasia of bone. Bone 1997; 21: 201-206.
125. Riminucci M, Fisher LW, Majolagbe A, Corsi A, Lala R, De Sanctis C, Robey PG, Bianco P. A novel GNAS1 mutation, R201G, in McCune-Albright syndrome. J Bone Miner Res 1999; 14: 1987-1989.
126. Weinstein LS. The stimulatory G protein α-subunit gene: mutations and imprinting lead to complex phenotypes. J Clin Endocrinol Metab 2001; 86: 4622-4626.
127. Hibbs RE, Rush HP. Albright's syndrome. Ann Intern Med 1952; 37: 587-593.
128. Collins MT, Shenker A. McCune-Albright syndrome: new insights. Curr Opinion Endocrinol Diabetes 1999; 6: 119-125.
129. Roman R, Johnson MC, Codner E, Cattani A, Garcia H, Mericq V, Boric A, Munoz M, Schneider R, Cassorla F. Clinical and molecular study of Chilean patients with McCune-Albright syndrome. Rev Med Chil 2001; 129: 1365-1372.
130. Karadag A, Riminucci M, Bianco P, Cherman N, Kuznetsov SA, Nguyen N, Collins MT, Robey PG, Fisher LW. A novel technique based on a PNA hybridization probe and FTET principle for quantification of mutant genotype in fibrous dysplasia/McCune-Albright syndrome. Nucleic Acids Res 2004; 32: e63.
131. Lietman SA, Ding C, Levine MA. A highly sensitive polymerase chain reaction method detects activating mutations of the GNAS gene in peripheral blood cells in McCune-Albright syndrome or isolated fibrous dysplasia. J Bone Joint Surg Am 2005; 87: 2489-2494.
132. Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, Hench K, McNemar A, Skerda M, Loriaux DL, et al. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog. J Clin Endocrinol Metab 1984; 58: 857-861.
133. Schmidt H, Kiess W. Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 1998; 11: 77-81.
134. Lee TC, Miller WL, Auchus RJ. Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab 1999; 84: 2104-2110.
135. Richton SM, Maclaren NK, McLaughlin JV, Raiti S. Albright's syndrome presenting as thyrotoxicosis: follow-up of a case. Pediatrics 1979; 63: 159-162.
136. Rao S, Colaco MP, Desai MP. McCune Albright syndrome (MCAS): a case series. Indian Pediatr 2003; 40: 29-35.
137. Chen CK, Tsai WY, Lee JS, Li YW, Hsieh FJ. Sexual precocity due to McCune-Albright syndrome: report of a case. J Formos Med Assoc 1993; 92: 174-177.
138. Cisternino M, Pasquino AM, Bozzola M, Balducci R, Lorini R, Pucarelli I, Segni M, Severi F. Final height attainment and gonadal function in girls with precocious puberty treated with cyproterone acetate. Horm Res 1992; 37: 86-90.
139. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1990; 20: 418-434.
140. Eugster EA, Shankar R, Feezle LK, Pescovitz OH. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. J Pediatr Endocrinol Metab 1999; 12: 681-686.
141. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH; McCune-Albright Study Group. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143: 60-66.
142. Saenger P, Rincon M. Precocious puberty: McCune-Albright syndrome and beyond. J Pediatr 2003; 143: 9-10.
143. Santen RJ. To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 2002; 87: 3007-3012.
144. Syed FA, Chalew SA. Ketoconazole treatment of gonadotropin independent precocious puberty in girls with McCune-Albright syndrome: a preliminary report. J Pediatr Endocrinol Metab 1999; 12: 81-83.
145. Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001; 86: 4887-4894.
146. Nunez SB, Calis K, Cutler GB, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88: 5730-5733.
147. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am 2003; 83: 973-994.
148. Kosloske AM, Goldthorn JF, Kaufman E, Hayek A. Treatment of precocious pseudopuberty associated with follicular cysts of the ovary. Am J Dis Child 1984; 138: 147-149.
149. Gesmundo R, Guanà R, Valfrè L, De Sanctis L, Matarazzo P, Marzari D, Lala R. Laparoscopic management of ovarian cysts in peripheral precocious puberty of McCune-Albright syndrome. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 571-575.
150. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab 1987; 64: 328-333.
151. Bennett JE. Antifungal agents. In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics, 10th Ed. Ch 49: Antimicrobial Agents. New York: McGraw-Hill, 2001; 1295-1312.
152. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985; 312: 1023-1028.
153. Reiter EO, Norjavaara E. Testoxicosis: current viewpoint. Pediatr Endocrinol Rev 2005; 3: 77-86.
154. Winter JSD, Couch RM, Muller J, Perry YS, Ferreira P, Baydala L, Shackleton CH. Combined 17-hydroxylase and 17,20-desmolase deficiencies: evidence for synthesis of a defective cytochrome P450c17. J Clin Endocrinol Metab 1989; 68: 309-316.
155. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003; 88: 3090-3098.
156. Feuillan PP, Jones J, Ross JL. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab 1995; 80: 1357-1360.
157. Geffner ME, Nagel RA, Dietrich RB, Kaplan SA. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. J Pediatr 1987; 111: 740-743.
158. Cremonini N, Graziano E, Chiarini V, Sforza A, Zampa GA. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995-bromocriptine combined treatment results. J Clin Endocrinol Metab 1992; 75: 1166-1169.
159. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-1759.
160. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005; 90:5627-5631.
161. Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 2006; 91: 2966-2966.
162. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002; 87: 3180-3186.
163. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001; 86: 5256-5261,
164. Chung KF, Alaghband-Zadeh J, Guz A. Acromegaly and hyperprolactinemia in McCune-Albright syndrome. Evidence of hypothalamic dysfunction. Am J Dis Child 1983; 137: 134-136.
165. Kovacs GL, Drago F, Acsai L, Tihanyi A, Scapagnini U, Telegdy G. Catecholamine utilization in specific rat brain nuclei after short-term, hyperprolactinaemia. Brain Res 1984; 324: 29-34.
166. Dent CE, Gertner JM. Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 1976; 45: 411-420.
167. Roth JG, Esterly NB. McCune-Albright syndrome with multiple bilateral cafe au lait spots. Pediatr Dermatol 1991; 8: 35-39.
168. Lain R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000; 89: 188-193.
169. Allgrove J. Biphosphonates. Arch Dis Child 1997; 76: 73-75.
170. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 953-954.
171. Matarazzo P, Lala R, Masi G, Andreo M, Altare F, de Sanctis C. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 (Suppl 3): 929-937.
172. van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology 1992; 184: 249-254.
173. Kitagawa Y, Tamai K, Ito H. Oral alendronate treatment for polyostotic fibrous dysplasin: a case report. J Orthop Sci 2004; 9: 521-525.
174. Giordano F, Serio P, Savasta S, Oliveri G, Genitori L. Craniofacial surgery in fibrous dysplasia. J Pediatr Endocrinol Metab 2006; 19 (Suppl 2): 959-604.
175. Samuel S, Gilman S, Maurer HS, Rosenthal IM. Hyperthyroidism in an infant with McCune-Albright syndrome: report of a case with myeloid metaplasia. J Pediatr 1972; 80: 275-278.
176. DiGeorge AM. Albright syndrome: is it coming of age? J Pediatr 1975; 87: 1018-1020.
177. Shelley WB. Alopecia with fibrous dysplasia and osteomas of the skin. A sign of polyostotic fibrous dysplasia. Arch Dermatol 1976; 112: 715-719.
178. Fischer JA, Bollinger A, Lichtlen P, Wellauer J. Fibrous dysplasia of the bone and high cardiac output. Am J Med 1970; 49: 140-146.
179. Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91: 2017-2020.
180. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006: 22: 578-579.